Symbiotec Pharmalab IPO

Listed Mainboard
Min Investment
₹14,820
15 Shares
Min Investment
₹14,820 · 15 Shares
Price Band ₹938–988
Lot Size 15 shares
Issue Size ₹1,757 Cr
Listed At ₹988.00 +0%
Subscribed 75.05×
Listed On BSE & NSE

Symbiotec Pharmalab IPO Listing Day Performance

Symbiotec Pharmalab listed on BSE & NSE on 01 September 2026 at ₹988.00, a 0% premium over the issue price of ₹988. A retail investor allotted one lot of 15 shares gained ₹0 at the listing price.

Issue price
₹988
upper band
Listing price
₹988.00
pre-open auction
Listing gain
+0%
+₹0 per share
Profit per application
+₹0
15 shares

GMP vs actual listing

Last GMP before listing₹185 (+18.7%)
GMP-implied listing₹1,173
Actual listing₹988.00
Difference−₹185 (−15.8%)

Demand going into listing

Subscribed overall75.05×
QIB181.2×
NII77.56×
Retail13.64×
Listing price = opening price from the exchange's pre-open call auction on listing day. Watch live price

Market Sentiment

Grey Market Premium What is GMP?
+₹185
+18.7% ▼ ₹15 since last update
Est. listing ₹1173
Upper price ₹988
GMP range ₹185 – ₹243
30 Aug · ₹240 01 Sept · ₹185
Updated 01 Sept, 12:03 am IST Unofficial grey-market data
GMP estimate ₹1173
Actual listing ₹988
Listed below the GMP estimate by ₹185 (-15.8%)
Subscription Status
QIB
181.20x
NII
77.56x
bNII (>10L)
87.34x
sNII (2-10L)
58.00x
Retail
13.64x
Employee
16.31x
Total
75.05x
Updated: Aug 27, 2026 5:06 pm IST
Analysis Score 78 / 100
Data: 80%
GMP Score · 44% weight 65
Subscription Score · 38% weight 100
Financial Health · 19% weight 63
Weighted average of the parts above; updates as GMP and subscription change. not investment advice.

IPO Details

Price Band₹938–988 per equity share
Face Value₹2 Per Equity Share
Lot Size 15 shares (Min ₹14,820)
Total Issue Size ₹1,757.00 crore
Fresh Issue₹150.00 crore
Offer For Sale₹1,607.00 crore
Fresh vs OFS
Fresh 9% · to the company OFS 91% · to selling shareholders
Issue TypeBook built Issue
Lead Managers JM Financial Ltd. , Avendus Capital Pvt. Ltd.
Registrar MUFG Intime India Pvt. Ltd.
PromotersAnil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP
Listing atBSE & NSE
BSE Code544889
NSE SymbolSYMBIOTEC
Listing Price₹988.00
Listing Gain+0.00%

Day-wise Subscription (times subscribed)

QIB
NII
Retail
Employee
Total
Each panel has its own scale.
Category Day 1 Day 2 Day 3 Day 4
QIB 0.35x 0.54x 0.59x 181.20x
NII 1.04x 3.00x 12.18x 77.56x
bNII > ₹10L 0.78x 2.46x 11.30x 87.34x
sNII 2-10L 1.58x 4.08x 13.95x 58.00x
Retail 0.95x 2.10x 5.05x 13.64x
Employee 1.56x 3.01x 5.86x 16.31x
Total 0.80x 1.85x 5.31x 75.05x

Market Lot Size

Category Lots Shares Amount (₹)
Retail Minimum 1 15 ₹14,820
Retail Maximum 13 195 ₹1,92,660
S-HNI Minimum 14 210 ₹2,07,480
S-HNI Maximum 67 1,005 ₹9,92,940
B-HNI Minimum 68 1,020 ₹10,07,760

IPO Reservation

QIB 20% NII 15% Retail 34.9% Anchor 29.9% Employee & others 0.2%
Category Shares Offered Shares %
QIB35,50,60819.96%
NII (HNI)26,62,95514.97%
bNII > ₹10L17,75,3049.98%
sNII < ₹10L8,87,6514.99%
Retail62,13,56234.93%
Employee33,4080.19%
Anchor53,25,90929.94%
Total1,77,86,442

Financial Analysis

Financial Data

EPS (Pre)
₹19.10
ROE
11.19%
ROCE
11.56%
RoNW
9.48%
EBITDA Margin
26.59%
NAV/Share
₹184.69
Revenue Growth
15.38%
Profit Margin
12.60%

Financial Performance

2026 vs 2025 Revenue +15.4% Profit (PAT) +13.5% Total Assets +12.7%
Metric 2024 2025 2026
Revenue 723.33 755.98 872.26
Expense 590.99 608.85 709.90
Profit (PAT) 100.06 96.79 109.90
Total Assets 1,294.79 1,579.65 1,780.79
Values in Crores (₹)

Peer Comparison

Company EPS P/E RoNW % NAV Income
Symbiotec Pharmalab This IPO 19.10 - 9.48 184.69 -
Concord Biotech Limited 24.78 61.07 14.00 - 1,054.90 Cr
Divi’s Laboratories Limited 96.75 87.80 16.50 631.00 10,560.00 Cr
Cohance Lifesciences Limited 4.69 95.02 7.00 - 2,268.55 Cr
Laurus Labs Limited 16.47 109.36 16.80 - 6,812.90 Cr
Peer median P/E 91.4x across 4 listed peers

Strengths & Risks

Strengths
  • Heavily oversubscribed — 75.1x overall (so far).
  • Strong institutional (QIB) demand — 181.2x.
  • Revenue grew 15% in the latest reported year.
  • Solid profit margin — 12.6%.
Risks & Concerns
  • Largely an offer for sale — most proceeds go to selling shareholders, not the company.

From this issue's live data. Not investment advice — read the RHP.

Company Information

Symbiotec Pharmalab at a glance

From the company's description: “Symbiotec Pharmalab is a pharmaceutical and biotechnology company with over 30 years of experience.”

Symbiotec Pharmalab is raising ₹1,757 crore through an IPO on the BSE and NSE mainboard. Of that, ₹150 crore is a fresh issue — new shares, with the money going to the company — and ₹1,607 crore is an offer for sale by existing shareholders, who keep those proceeds; 8.5% of the issue therefore reaches the business. Main stated uses of the fresh money: Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company (₹113 crore).

Revenue went from ₹723 crore in 2024 to ₹872 crore in 2026, up 21% over 2 years. Profit after tax went from ₹100 crore to ₹110 crore, a net margin of 13% in the latest year.

Written from the issue's offer-document figures shown on this page. Not investment advice.

Company Contact Information

Symbiotec Pharmalab Ltd., 385/2,, Pigdamber, Rau,, Mhow,, Indore, Madhya Pradesh, 453331

Objects of the Issue

Purpose Amount (Cr)
Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company 112.50
General corporate purposes -

Resources & Documents

Anchor Investors

Anchor Bidding Date
August 21, 2026
Shares Offered to Anchors
53,25,909
Lock-in End (30 Days, 50%)
September 27, 2026
Lock-in End (90 Days, 50%)
November 26, 2026

Symbiotec Pharmalab IPO - Quick Take

Symbiotec Pharmalab has set a price band of Rs 938–Rs 988 per share for an issue size of Rs 1,757 crore. The stock listed flat against its issue price.

The issue is promoted by Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP with JM Financial Ltd., Avendus Capital Pvt. Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Co… (Rs 113 crore) and general corporate purposes.

On fundamentals, the company is posting revenue growth of 15.4%, a profit margin of 12.6%, return on equity of 11.2% in its most recent reported period. Listed peers in this segment include Concord Biotech Limited (P/E 61.07x) and Divi’s Laboratories Limited (P/E 87.80x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.

On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.

Symbiotec Pharmalab IPO: Lead Manager & Registrar Track Record

How the firms running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Symbiotec Pharmalab itself, so they describe what came before it.

Mainboard IPOs, last 12 months
  • Symbiotec Pharmalab listed at +0% on day one; the median of 113 listings was +7% (better than 21% of them).
  • Subscribed 75.05x against a median of 20.43x across 111 issues (higher than 74%).
  • Average listing-day move across all 114 Mainboard listings we track: +13.6%.
Lead manager and registrar record on other IPOs we track
Firm Other IPOs Listed at / above issue Avg move Median
JM Financial Ltd. Lead manager 32 32 MB · 0 SME 86% 24 of 28 +16% +6.1%
Avendus Capital Pvt. Ltd. Lead manager 6 6 MB · 0 SME 83% 5 of 6 +3.3% +4.9%
Motilal Oswal Investment Advisors Ltd. Lead manager 20 20 MB · 0 SME 84% 16 of 19 +11.7% +7%
Nomura Financial Advisory & Securities (India) Pvt. Ltd. Lead manager 2 2 MB · 0 SME 50% 1 of 2 +14.5% +14.5%
MUFG Intime India Pvt. Ltd. Registrar 66 44 MB · 22 SME 74% 46 of 62 Check allotment →
Recent listings managed by JM Financial Ltd. (5)

Best: Tempsens Instruments +111.3% · Weakest: Turtlemint Fintech −11.3%

IPOListedListing-day move
SFC Environmental 03 Nov 2026 +7.6%
Jio Platforms 28 Oct 2026 +21.4%
Paras Healthcare 28 Oct 2026 +3.9%
Zetwerk 23 Oct 2026 +5.5%
Tonbo Imaging 23 Oct 2026 +66%
Recent listings managed by Avendus Capital Pvt. Ltd. (5)

Best: SEDEMAC Mechatronics +13.5% · Weakest: Amagi Media Labs −12.2%

IPOListedListing-day move
Zetwerk 23 Oct 2026 +5.5%
Sahajanand Medical 23 Oct 2026 +7.9%
NSE 24 Sep 2026 +0.8%
LEAP India 14 Aug 2026 +4.3%
SEDEMAC Mechatronics 11 Mar 2026 +13.5%
Recent listings managed by Motilal Oswal Investment Advisors Ltd. (5)

Best: CMR Green Technologies +43.4% · Weakest: Waterways Leisure Tourism −15.7%

IPOListedListing-day move
EAAA India Alternatives 02 Nov 2026 +0.6%
Sahajanand Medical 23 Oct 2026 +7.9%
Fusion CX 22 Oct 2026 +5.5%
NSE 24 Sep 2026 +0.8%
Manipal Payment 17 Sep 2026 −2.1%
Recent listings managed by Nomura Financial Advisory & Securities (India) Pvt. Ltd. (2)

Best: Dhoot Transmission +37.8% · Weakest: Clean Max Enviro −8.8%

IPOListedListing-day move
Dhoot Transmission 17 Aug 2026 +37.8%
Clean Max Enviro 02 Mar 2026 −8.8%
What a lead manager does

A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.

What a registrar does

Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.

Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.

Frequently Asked Questions

Symbiotec Pharmalab listed at Rs 988.00 on 01 September 2026, against an issue price of Rs 988 — a 0% premium.

+0% at the listing price — Rs 0 per share, or Rs 0 on the minimum retail application of 15 shares.

The price band of Symbiotec Pharmalab IPO is Rs 938 to Rs 988 per share. Face value is Rs 2 per share.

The total issue size of Symbiotec Pharmalab IPO is Rs 1,757 crore, comprising fresh issue of Rs 150 crore and offer for sale (OFS) of Rs 1,607 crore.

The lot size of Symbiotec Pharmalab IPO is 15 shares. The minimum application is 1 lot (15 shares), requiring an investment of Rs 14,820. Maximum retail application is 13 lots (195 shares, approx Rs 1,92,660).

Symbiotec Pharmalab IPO opens for subscription on August 24, 2026 and closes on August 27, 2026. Anchor investor bidding is scheduled for August 21, 2026.

The expected allotment date for Symbiotec Pharmalab IPO is August 28, 2026. Refunds for unsuccessful applicants are expected on August 31, 2026.

Symbiotec Pharmalab IPO is scheduled to list on September 01, 2026 on both BSE and NSE. BSE script code: 544889, NSE symbol: SYMBIOTEC.

The last GMP (Grey Market Premium) recorded for Symbiotec Pharmalab IPO before listing was +Rs 185 (+18.7% over issue price). The shares actually listed at Rs 988 (+0.00% versus the issue price). GMP only estimates the listing price and stops mattering once the shares trade.

Symbiotec Pharmalab IPO was subscribed 75.05 times overall by the close of bidding — retail at 13.64x, QIB at 181.20x, NII at 77.56x.

Based on the final retail subscription of 13.64x for Symbiotec Pharmalab IPO, the estimated retail allotment probability is approximately 8.4%. This is a low probability — approximately 8 out of every 100 retail applications may receive allotment.

The registrar for Symbiotec Pharmalab IPO is MUFG Intime India Pvt. Ltd. After the allotment date, you can check your allotment status on the registrar's official website by entering your PAN, application number, or demat account details. Allotment status is also available on the BSE and NSE websites.

The book running lead manager(s) for Symbiotec Pharmalab IPO are JM Financial Ltd., Avendus Capital Pvt. Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt. Ltd.

The promoter(s) of Symbiotec Pharmalab are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.

Symbiotec Pharmalab IPO GMP — What It Means

Its last GMP before listing was 18.7%. Of the 26 Mainboard IPOs we have tracked with a final GMP between 10% and 25%, 23 listed above, 2 flat and 1 below the issue price; Symbiotec Pharmalab listed flat.

See the full Symbiotec Pharmalab GMP history and trend, or learn how grey market premium works and how reliable it is.

Related IPO

Same sector or same stage as Symbiotec Pharmalab
Side by side: GMP, subscription, valuation, financials and listing performance.
0 Comments

No comments yet. Be the first to share your opinion!

GMPUpdate